Qiming Venture Partners

TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer.

DK Medtech, founded in 2015 and headquartered in Suzhou, China, specializes in the development and production of balloon catheter medical devices. The company is recognized as a leader in the medical device industry, focusing on innovative technologies that aim to meet the evolving challenges in healthcare. Through its commitment to excellence, DK Medtech strives to create impactful solutions that enhance patient care and improve medical outcomes.

XSKY Beijing Data Technology Corporation Limited is a Chinese company that specializes in software-defined infrastructure products and services aimed at delivering innovative storage solutions for enterprises. By integrating internet carrier operations and mainstream open-source technologies, XSKY offers scalable storage solutions that facilitate cost-effective horizontal expansion for data centers. The company is a significant contributor to the open-source storage system Ceph, ranking among the top three globally and leading in China for source code contributions. Additionally, XSKY is the exclusive storage solution partner of Red Hat China and collaborates with major IT companies like Intel, Samsung, Dell, and Mellanox. Its products are utilized by early adopters in various sectors, including financial services, transportation, telecommunications, and energy, highlighting its commitment to enhancing data management and infrastructure innovation.

Demei Medical specializes in the design and manufacture of sports medicine surgical equipment, intraoperative consumables, and rehabilitation products, with a focus on arthroscopic surgery and sports rehabilitation products.

Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.

Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

Erwan Technology is an online education provider based in Dalian Shi, Liaoning, China, specializing in financial investment education for Chinese middle-class families. Founded in 2016, the company offers a variety of paid educational modules, including live broadcasts, boutique investment courses, and hands-on workshops, aimed at equipping users with essential financial skills. With a focus on making financial education accessible, Erwan Technology has reached over 10 million middle-class students across 34 provincial administrative regions, establishing itself as the largest online investment education platform by user base and ranking among the top three platforms by revenue. The company’s mission is to enhance financial literacy by covering topics such as investment strategies, risk management, and wealth management.

New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.

Mafengwo is a Chinese travel social networking site that allows users to share and explore travel experiences. It features over one million user-generated travel guides and more than five million ratings and reviews, covering a wide range of travel-related information such as hotels, flights, travel routes, visas, and insurance. Since its inception, Mafengwo has served more than 25 million users and emphasizes user experience by continually enhancing its platform for sharing travel insights. Its core product, the Travel Guide, includes information on over 95% of global travel destinations and has achieved over 100 million downloads. In 2012, the platform expanded its offerings by integrating booking services from various providers, thereby enhancing its utility for travelers. The company has also attracted significant investment, raising $15 million in Series B funding to support its growth and development.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Schrödinger develops a computational platform that facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform.

Tuhu is a prominent integrated online and offline platform for automotive services in China, catering to car owners' diverse needs. Operating in over 260 cities, Tuhu offers same-day or next-day delivery and installation services for automobile after-sales products. The company utilizes its website, mobile app, call center, and third-party e-commerce platforms to deliver a digitalized and on-demand service experience. Tuhu's platform addresses a wide range of automotive service demands, including the replacement of tires and chassis parts, as well as auto maintenance, repair, and detailing. By connecting car owners with suppliers and automotive service stores, Tuhu effectively fulfills the requirements of most passenger vehicle models sold in China.

MicroPoint Bioscience, Inc. is a Chinese company focused on biochip research and development, specializing in vitro point-of-care testing (POCT) equipment and biological diagnostic test reagent cards. The company offers a product line called Lab On a Chip, which utilizes microelectromechanical systems (MEMS) technology to deliver microfluidic bio-diagnostic testing solutions. These products are designed to assist medical care providers in the early diagnosis and monitoring of critical diseases, including vascular diseases and tumors. In addition to medical applications, MicroPoint Bioscience also serves sectors such as environmental protection, food safety, and scientific research, customizing its offerings to meet specific customer needs. Their bedside immediate diagnosis chip and examination instruments aim to provide cost-effective solutions for early disease detection and monitoring.

ACEA Biosciences, founded in 2002 and based in San Diego, California, is a biotechnology company specializing in the development and commercialization of advanced microelectronic systems for cell-based assays. The company pioneered real-time, label-free cell analysis technology, marketed globally under the xCELLigence brand, which has garnered over 800 customers and more than 350 peer-reviewed publications. ACEA's innovative iCELLigence instrument, featuring wireless connectivity, enhances accessibility to this technology. In addition to its Life Technology Business Unit, ACEA operates a Therapeutics Business Unit focused on oncology drug discovery and development, utilizing its biosensor technology and a proprietary library of over one million small molecules. The company currently has a program in phase II clinical trials in China, along with several early clinical and preclinical leads. With a strong commitment to scientific collaboration, ACEA Biosciences aims to drive innovation in research and healthcare globally.

Meituan Bike (formerly Mobike) is a Chinese fully station-less bicycle-sharing system. It develops mobile apps for users to find and use bicycles to travel anywhere. Davis Wang Xiao Feng, Hu Wei Wei, and Xia Yi Ping founded Mobike on January 27, 2015, with its headquarters in Beijing, China. Mobike raised $600 million in Series E funding led by Tencent, bringing the firm's fundraising in 2017 alone to nearly US$1 billion in June 2017. It became worth US$3 billion in the same month. Chinese web company Meituan-Dianping acquired Mobike for US$2.7 billion in April 2018. Parent company Meituan-Dianping announced name change from Mobike to Meituan Bike on January 23, 2019 as part of an ongoing integration.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

ACEA Biosciences, founded in 2002 and based in San Diego, California, is a biotechnology company specializing in the development and commercialization of advanced microelectronic systems for cell-based assays. The company pioneered real-time, label-free cell analysis technology, marketed globally under the xCELLigence brand, which has garnered over 800 customers and more than 350 peer-reviewed publications. ACEA's innovative iCELLigence instrument, featuring wireless connectivity, enhances accessibility to this technology. In addition to its Life Technology Business Unit, ACEA operates a Therapeutics Business Unit focused on oncology drug discovery and development, utilizing its biosensor technology and a proprietary library of over one million small molecules. The company currently has a program in phase II clinical trials in China, along with several early clinical and preclinical leads. With a strong commitment to scientific collaboration, ACEA Biosciences aims to drive innovation in research and healthcare globally.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.